Mini-PCNL Versus Standard-PCNL For The Management of 20-40 mm Size Kidney Stones

NCT ID: NCT02635048

Last Updated: 2020-03-05

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 1980 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-01-01
• Study Completion Date: 2019-08-20

Brief Summary

Percutaneous nephrolithotomy (PCNL) has been considered as the first-line choice for the management of >20mm kidney stones. The traditional nephrostomy tract of PNL was dilated to 24-30F, which is referred to as "Standard-PCNL". Standard PNL has an ideal stones free rate (SFR), however, at the cost of severe morbidity. To decrease the disadvantages related to standard PNL, "mini-perc" or "mini-PCNL", 20F or less, was first introduced to pediatric procedure in 1997, and subsequently implemented in adults with the expectation of similar SFR and low morbidity in the past twenty years. Although abundant efforts have been done, whether mini-perc outweigh standard-PNL for the treatment of >20mm calculis in terms of efficiency and safety remains controversial.

To solve this problem, we performed this multicenter, parallel, open-label randomized controlled trial (RCT).

Detailed Description

To evaluate the efficacy and safety of mini-PCNL versus standard-PCNL for the management of 20-40 mm size kidney stones.Investigators plan to do a multicenter, parallel, open-label randomized controlled trial (RCT). There are 20 hospitals included in this study, including The First Affiliated Hospital of Guangzhou Medical University, Baoshan No.2 People's Hospital, The second Affiliated Hospital of Harbin Medical University, The First Affiliated Hospital of Fujian Medical University, People's Hospital of Nanhai District, Yichang Yiling Hospital, Suzhou Municipal Hospital, Jining NO.1 People's Hospital, The First Affiliated Hospital of Gannan Medical University, The General Hospital of Shenyang Military, Shanghai General Hospital, Qingyuan People's Hospital, The second Affiliated Hospital of Kunming Medical University, Beijing Chuiyangliu Hospital, Fujian Medical University Union Hospital, ShengJing Hospital of China Medical University, 181st hospital of Chinese People's Liberation Army, The First Affiliated Hospital of Guangxi Medical University, China-Japan Union Hospital, Jilin University, Jiangmen Hospital of Zhongshan University.

Each center performs more than 500 PNL procedures per year. Ethics committee approval was obtained at each site and informed consent was taken from each patient. The primary endpoint was the one-session SFR and the secondary endpoints included intraoperative and postoperative parameters.

This study will be started at January,2016 and ended at November ,2019. The SFR of sPNL and mPNL was assumed to be 83% and 89% respectively, based on the earlier data. -10% was considered as a non-inferiority margin. the type-1 error (α) was set to 0.05 and the power (1-β) to 0.8. Sampling ratio was 1. According to the formulas of 2-sample non-inferiority test comparing two proportions, the minimum sample size for each group was 923 using a power and sample size calculator (HyLown Consulting, Atlanta). Considering the patients lost to follow-up and consent withdrawals, the number was increased to 1000 patients in each group.

Randomization We used SPSS software to generate 2000 random numbers in a table with a ratio of 1:1 ("0" for sPNL and "1" for mPNL). A protocol-blinded coordinator revealed the assignment in sequence to the center once the consent was signed and surgery was scheduled. The number of included patients was not equally distributed among the centers.

Quality control A standard operating procedure (SOP) was made and approved by the principal investigator of each center. Routine monitoring visits to all centers were carried out every month.

Intravenous urography (IVU) and 2 mm non-contrasted CT were done in all patients. CT value was measured with a consistent software in each center. Patients had negative urine culture before treatment. Intravenous single dose of 1st/2nd-generation cephalosporin or ciprofloxacin was administered 30 mins before and after surgery as antibiotic prophylaxis.

All the endoscopic procedures were performed by only one designated experienced surgeon (≥100 procedures per year in both sPNL and mPNL) in each center. All the procedures were performed under general anesthesia and in the prone position. A 5 Fr open-ended ureteral catheter was placed to the renal pelvis through a guide wire. The use of fluoroscopic or/and ultrasonic guidance was determined by the surgeons' preference. An 18-gauge needle was used for puncture. As shown in Fig. 1, the access tract was gradually dilated with fascial introducers (Reborn Medical®) up to 18F (mPNL) or 24F (sPNL). A peel-away sheath was used (Reborn Medical®). The stone was fragmented by pneumatic LithoClast®, or holmium laser with a 550-um laser fiber (Lumenis® and an energy setting of 30-50 W) or ultrasonic lithotripsy (EMS®, only sPNL group). The stone free status was routinely evaluated by fluoroscopy (radiopaque stone) or ultrasound (radio lucent stone). An immediate second-look or another puncture would be performed if needed. A 6 Fr double J stent was inserted for 4 weeks. A 16-18F silastic nephrostomy tube was placed and removed before discharge. Indication for tubeless/total tubeless: absence of major perforation of collecting system, bleeding and/or complete stone clearance.

K.U.B. (kidney-ureter-bladder) plain radiograph and renal ultrasound were used to evaluate the residual stones before discharge. If there was a discrepancy between the presence of residual stones between the KUB and renal ultrasound, a 2 mm non-contrast CT was ordered to better delineate the presence of residual stones and their impact on the clinical management. The status of residual stones was according to the reports assessed by two protocol-blinded radiologists. If the largest residual stone was larger than 6 mm, SWL, RIRS or URL would be recommended before removing double J stent. The one-session SFR (primary outcome) was determined at one month after removing double J stent and defined as either the absence of any residual stone fragments or the presence of clinically insignificant residual stone fragments (CIRFs), without any auxiliary procedures.

The hematocrit drop was measured at 8 am on postoperative day 1. The indications for transfusion was strictly monitored according to the guideline of Chinese Society of Blood Transfusion (hemoglobin less than 70g/l or a progressive decrease in hemoglobin after surgeries). Consideration of angiography and selective angio-embolization for patients with significant macroscopic hematuria in the urine as well as progressive decrease in hemoglobin or unstable hemodynamics. Visual analogue scale (VAS) was used as a pain scale for quantification of postoperative pain at 24h after surgeries.14 VAS was evaluated by two protocol-blinded nurses. Patients with VAS greater than 5 were given nonsteroidal anti-inflammatory drugs. Stone composition was analyzed using uniform instruments (Fourier Transform-Infrared Spectrometry, Thermo®) and method in all participated centers.

Data collection and definitions of parameters The characteristics of patients and clinical outcomes were recorded according to the pre-established case report form (CRF) . Surgical outcomes were predicted preoperatively according to the S·T·O·N·E nephrolithometry. The stone size was the largest diameter of a single stone or the summation of the largest diameters of multiple stones. Operation time was defined as the time from puncture to the placement of the nephrostomy tube or removing the access sheath in cases with tubeless or total tubeless. Septic shock was identified using the clinical criteria of persisting hypotension requiring vasopressor therapy to maintain mean mean artery pressure (MAP) ≥65 mmHg and having a serum lactate level ≥ 2 mmol/L (>18mg/dL) despite adequate fluid resuscitation.

Statistical analysis Statistical analysis was performed using SPSS 20·0. Continuous variables were analyzed using Student's t-test to compare the two means. Categorical variables between groups were analyzed using the chi-squared or Fisher's exact tests. Primary endpoints and some key secondary endpoints were analyzed in both intention-to-treat (ITT) and per-protocol (PP) population. Odds ratio (OR) for sPNL compared with mPNL in categorical variables. Mean difference for sPNL compared with mPNL in continuous variables. P <0·05 was considered statistically significant.

Conditions

Kidney Calculi

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Group 1

Patients in Group 1 undergo mini percutaneous nephrolithotomy

Group Type: OTHER

Mini Percutaneous Nephrolithotomy

Intervention Type: PROCEDURE

patients undergo PNCL with 18Fr nephrostomy tract

Group 2

Patients in Group 2 undergo percutaneous nephrolithotomy

Group Type: OTHER

Percutaneous Nephrolithotomy

Intervention Type: PROCEDURE

patients undergo PNCL with 24Fr nephrostomy tract

Interventions

Mini Percutaneous Nephrolithotomy

patients undergo PNCL with 18Fr nephrostomy tract

Intervention Type: PROCEDURE

Percutaneous Nephrolithotomy

patients undergo PNCL with 24Fr nephrostomy tract

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

1. Patients consent for percutaneous renal stone removal

2. Age 18 to 70 years

3. Normal renal function

4. ASA score Ⅰ and Ⅱ

5. Renal stones 20-40mm

Exclusion Criteria

1. Patients with solitary kidney.

2. Uncorrected coagulopathy and active urinary tract infection (UTI)

3. Morbid obese patients

4. Patients who underwent transplant or urinary diversion.

5. Congenital abnormalities.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Baoshan No.2 People's Hospital

UNKNOWN

Sponsor Role: collaborator

The Second Affiliated Hospital of Harbin Medical University

OTHER

Sponsor Role: collaborator

First Affiliated Hospital of Fujian Medical University

OTHER

Sponsor Role: collaborator

People's Hospital of Nanhai District, Foshan

UNKNOWN

Sponsor Role: collaborator

Yichang Yiling Hospital

UNKNOWN

Sponsor Role: collaborator

Suzhou Municipal Hospital

OTHER

Sponsor Role: collaborator

First Affiliated Hospital of Gannan Medical University

OTHER

Sponsor Role: collaborator

General Hospital of Shenyang Military Region

OTHER

Sponsor Role: collaborator

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

OTHER

Sponsor Role: collaborator

The Second Affiliated Hospital of Kunming Medical University

OTHER

Sponsor Role: collaborator

Beijing Chuiyangliu Hospital

OTHER_GOV

Sponsor Role: collaborator

Fujian Medical University Union Hospital

OTHER

Sponsor Role: collaborator

Shengjing Hospital

OTHER

Sponsor Role: collaborator

181st hospital of Chinese People's Liberation Army

OTHER

Sponsor Role: collaborator

First Affiliated Hospital of Guangxi Medical University

OTHER

Sponsor Role: collaborator

Jiangmen Central Hospital

OTHER

Sponsor Role: collaborator

China-Japan Union Hospital, Jilin University

OTHER

Sponsor Role: collaborator

The Sixth Affiliated Hospital of Guangzhou Medical University

OTHER

Sponsor Role: collaborator

Jining First People's Hospital

OTHER

Sponsor Role: collaborator

The First Affiliated Hospital of Guangzhou Medical University

OTHER

Sponsor Role: lead

Responsible Party

Guohua Zeng

Vice president

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Guohua Zeng, PH.D & MD

Role: PRINCIPAL_INVESTIGATOR

The First Affiliated Hospital of Guangzhou Medical University

Locations

Department of Urology, Minimally Invasive Surgery Center, The First Affiliated Hospital of Guangzhou Medical University

Guangzhou, Guangdong, China

Countries

China

Other Identifiers

MRER(67)2015

Identifier Type: -

Identifier Source: org_study_id